INTRODUCTION
Adult primary immune thrombocytopenia (ITP) is an acquired autoimmune disease characterized by increased platelet destruction, impaired megakaryocyte maturation with reduced platelet production and possible hemorrhagic complications. The incidence is nearly 30 new cases per million annually. 1 ITP is a chronic condition presenting most commonly in females and elderly patients, often with an insidious onset and varying severities of thrombocytopenia.
Glucocorticoids, the standard first line of treatment for patients with symptomatic disease, 2 enable the recovery of platelet count in 70-80% of cases; however, in most cases, steroid tapering or withdrawal is followed by a drop in platelet count and the need for additional treatment.
Splenectomy still represents the standard salvage therapy, with the caveat that ~40% of patients either do not respond or relapse after surgery, 3 ~10% experience perioperative or delayed infections and some develop surgical complications, though rarely fatal. 3 Recently, romiplostim and eltrombopag, two new thrombopoietin receptor agonists, have shown potent activity in ITP; 4, 5 however, these agents do not act on the underlying disease mechanism and therapeutic efficacy is dependent upon continual administration. Recently, the use of high-dose dexamethasone given in a single 4-day course (40 mg/d orally) as first-line treatment for adult ITP patients resulted in an 85%
initial response and more importantly, a 42% sustained response (SR) rate (i.e. platelet count > 50 x 10 9 /L six months after initial treatment). 6 Rituximab (MabThera, Roche) is a chimeric monoclonal antibody 7 highly specific for the CD20 antigen, which is expressed only by mature B-cells. Its administration is accompanied by marked, though transient, B-cell depletion 8 and this effect has been exploited for the treatment of several autoimmune disorders with encouraging results. [9] [10] [11] [12] [13] [14] [15] Various uncontrolled reports have described the activity of rituximab administered as a weekly infusion of 375 mg/m 2 for 4 consecutive weeks as a single agent salvage treatment in ITP. [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] Despite differences in patient characteristics, results from these studies showed 40% -70% overall early response rates with 20% -50% complete response rates, 20% -40% medium-term relapse rates, nearly 40% SR rates and splenectomy-sparing
For personal use only. on July 9, 2017. by guest www.bloodjournal.org From capacity in a substantial number of patients. 26 These studies reported also possible significant toxicities including death (not necessarily attributable to rituximab) in nearly 3% of cases. 25 The principal mechanism of rituximab action in ITP appears strictly related to B-cell depletion and the consequent inhibition of several B-cell pathologic activities, such as the production of autoantibodies specific for platelet and megakaryocyte glycoproteins (GPIIb/IIIa and Ib/IX), [27] [28] [29] cytokine secretion, and antigen-presenting cell activity. These effects may explain the rapid kinetics of platelet recovery observed in the majority of responders. Recent observations of the reversion of several baseline T-cell abnormalities in ITP patients who responded to rituximab [30] [31] suggest that rituximab may have an indirect regulatory effect which may help explain its long-term therapeutic effect.
To date, no prospective randomized studies evaluating rituximab efficacy in ITP have been performed. We report the results of the first prospective phase III study comparing the efficacy of dexamethasone plus rituximab vs. dexamethasone alone in treatment-naïve adult ITP patients.
METHODS

Study design
This randomized, open-label, phase III, multicenter study began in June 2005; enrollment was stopped in June 2007. The study consisted of two phases: the treatment phase (ML18542 study)
lasting from the time of enrollment up to Month 6, and an observational follow-up phase which lasted from Months 6 -36 ( Figure 1 ).
Patients
Twenty-two Italian academic centers or hospitals participated in this study. The study protocol was approved by the Institutional Review Boards of each participating center and written informed consent was obtained from all patients prior to study entry, in accordance with the Declaration of Helsinki. We enrolled treatment-naïve patients (any prior dose of corticosteroids or other immunesuppressive agents was an exclusion criteria), ≥ 18 years old, with a diagnosis of ITP according to asymptomatic, chronic ITP which subsequently worsened were included in the study.
The study population consisted mainly of patients with newly-diagnosed ITP (85 patients; Table 1) assessed according to recently-published criteria 32 , but also included treatment-naïve patients with persistent or chronic disease (16 patients; Table 1 ).
Treatment
Patients were randomized 1:1 to receive dexamethasone with or without rituximab. A daily dose of 40 mg oral dexamethasone was administered to both arms for 4 consecutive days (Days 1-4). 
Assessments and outcome measures during the treatment phase
The primary objective of the study was to compare the rates of SR (defined as platelet count ≥ 50 x 10 9 /L at Month 6). We selected platelet count instead of clinical signs of bleeding as the main efficacy parameter in order to eliminate any potential bias in assigning the grade of bleeding.
Platelet count was evaluated weekly during the first month and subsequently at bi-weekly intervals until the end of Month 6.
Patients who failed therapy, requiring further treatments in the interval between Day 28 and Month 6, were considered failures. The same efficacy parameters were also adopted to evaluate clinical efficacy in those patients who underwent dexamethasone plus rituximab salvage therapy. In this group, the onset of salvage therapy was considered as Day 1.
The secondary objectives of the study were the following: hematological response (platelet count ≥ In order to evaluate the levels of B-cell depletion and changes in immunoglobulin levels during the study period, the following analyses were performed at baseline and at monthly intervals: peripheral blood immune-phenotypic analysis of the CD20 lymphoid marker, and serum levels of IgG, IgA and IgM. 
Statistical analysis
Based on the results from Cheng et al., 6 this study was designed for an 80% probability to detect an improvement in SR from 40% of patients treated with dexamethasone and up to 60% of patients treated with dexamethasone plus rituximab, with a one-sided overall significance level of 5%. To account for the evaluation of toxicity, the sample size was adjusted from 154 to an overall size of 198 patients, assuming a 10% dropout rate, to capture > 11% grade 3-5 AEs in the experimental arm in comparison with an expected 2% in the dexamethasone arm. Three interim analyses were performed with every 50 enrolled patients to assess the necessity for early stopping for safety and efficacy reasons. The study would be stopped when a 50% relative difference in SR was demonstrated (α 0.017; Bonferroni adjustment) or if a greater than expected toxicity was observed in the experimental arm (>26%, > 16%, >12.5% at each safety checkpoint, respectively). Results were analyzed according to the intention to treat (ITT) population, which included all randomized patients who received the first dose of dexamethasone. In the cases of missing platelet count for premature discontinuations, the last observation carried forward approach was adopted. Patients who switched to salvage therapy in the dexamethasone arm and any patient requiring steroids or IVIg therapy after Day 28 in both arms were counted as SR failures. Differences in SR and toxicity rates were assessed with the χ2 or Fisher test, depending on the assumption check. An exploratory logistic regression model was applied to the SR data, including the effect of treatment and rescue therapy as covariates; results were expressed as odds ratios and 95% confidence intervals (C.I.).
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RESULTS
Treatment phase
Accrual and clinical characteristics
comprised the safety and ITT populations. Two patients could not be assessed because they did not receive any study drug after randomization (1 patient in the experimental arm because of no ITP diagnosis, and 1 patient in the dexamethasone arm because of previous treatment received). Both arms were balanced with respect to baseline characteristics (Table 1) .
Efficacy Compliance and additional therapy
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A total of 37 out of 101 patients, 14 /L (± 61) in the combination arm).
Sustained response (SR)
Analysis of the ITT population indicated that SR was higher amongst patients in the experimental arm compared to those in the dexamethasone arm (63% vs. 36 %, P=0.004, difference=27%, 95%
C.I.: 7.9-45.5) (Table 2A) . A similar pattern was observed for SR 100 and SR 150 (Table 2A) 27/41 (66%), P= 0.395, respectively).
For
Early response
During the early response assessment (ITT population), 28 out of 52 patients (54%) in the dexamethasone arm were considered non-responders (11 with platelet count < 50 x 10 9 /L, 17
receiving salvage therapy or taking concomitant steroids and/or IVIg); 31 out of 49 patients (63%)
were non-responders in the experimental arm (8 with platelet count < 50 x 10 9 /L, 23 taking concomitant steroids and/or IVIg).
Salvage therapy with dexamethasone plus rituximab
Twenty-seven patients (52%) initially allocated to receive dexamethasone monotherapy who failed to achieve SR received salvage treatment with dexamethasone plus rituximab, 18 in Month 2, 7 in Month 3 and 2 in Month 5 from the start of treatment. In this subgroup, compliance to dexamethasone and rituximab was 100%. The rates of SR, SR 100 and SR 150 were 56%, 44% and 37%, respectively (Table 2B) .
Safety
Due to the early stopping of the trial, the safety evaluation was performed over a shorter period than initially planned. Table 3 (Table 3 ). In the experimental arm, one patient required hospitalization because of platelet decrease and/or bleeding unrelated to study drug during salvage therapy; another patient required hospitalization one month after the end of rituximab treatment for interstitial pneumonia with a probable relation to study drug. No specific microbiological agents were detected and the patient recovered after treatment with levofloxacin plus ceftriaxone and azithromycin. One patient experienced supra-ventricular tachycardia during the first administration of rituximab and one patient experienced seizure during the salvage treatment: both were probably related to study drug
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Immunologic assessment
The baseline levels of IgG, IgA, IgM and CD20-positive lymphocytes were similar in both arms.
After therapy, a slight reduction in mean IgG was observed in the dexamethasone arm (Baseline vs. 
Observational follow-up phase
Eighty patients (15 in the dexamethasone arm, 41 in the experimental arm and 24 in the dexamethasone plus rituximab salvage therapy group) were followed-up beyond Month 6 for a median observation period of 20 months (range: 4-40 months). Twenty-one patients were not evaluable for this part of the study, as 9 were lost to follow-up during the study period.
Safety
One case of Herpes zoster reactivation was documented at Month 22 in a patient initially allocated to the dexamethasone arm who then received dexamethasone plus rituximab salvage therapy. No other infectious, delayed toxic events or deaths were registered.
Efficacy
Fifty-four out of 80 patients achieved a SR and could be evaluated for relapse rate and RD beyond Month 6. This group included 13 patients from the dexamethasone arm who were observed after 
DISCUSSION
We report results from the first randomized clinical trial evaluating the efficacy of rituximab in ITP.
Our results suggest that the addition of rituximab to a single course of dexamethasone therapy improves outcomes in treatment-naïve patients with ITP, when used as first-line or salvage therapy.
The inclusion of rituximab to the dexamethasone-based treatment regimen resulted in improved SR rates compared to dexamethasone alone (63% vs. 36%). Furthermore, the dexamethasone-rituximab regimen was effective as salvage therapy (SR 56%) in the subgroup of patients refractory to dexamethasone monotherapy.
We chose to assess the efficacy of rituximab in treatment-naïve patients in order to minimize any potential bias in patient baseline characteristics with respect to prior therapies. A single course of dexamethasone treatment (40 mg daily for 4 days) was selected as the comparator treatment based on the data of Cheng et al. 6 Indeed, comparison of the data obtained from our dexamethasone arm 34 However, these findings need to be confirmed.
We administered rituximab at the standard dosage of 375 mg/m 2 weekly for 4 weeks, according to the regimen adopted for non-Hodgkin's lymphoma (NHL), previous findings in ITP and other autoimmune disorders. The first rituximab infusion was administered on Day +7 in order to allow study physicians to confirm the diagnosis and establish platelet count increase or stabilization upon dexamethasone treatment.
Previous studies have demonstrated the therapeutic activity of rituximab and its long-term effects in patients with relapsed/refractory ITP. [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] However, it is difficult to compare these results with those from our study, due to differences in study methodology including patient selection criteria and the parameters used to assess response. Stasi et al. 17 showed that 10 out of 25 patients responded to rituximab and this response was maintained for 6 months or longer in 7 (28%) patients. GarciaChavez et al. 23 reported a 67% sustained response rate in 18 pretreated ITP patients; Godeau et al. 26 reported promising 1-year responses in 40% of patients. With one exception, 23 our data compare well with other studies in terms of long-term response (63% vs. nearly 40%), corroborating the hypothesis that better long-term effects of rituximab can be achieved when administered earlier in the course of the disease. [21] [22] In contrast to published findings, 20, 26 we could not confirm the prognostic significance of age or any other clinical or biological factors including gender, platelet count, lymphocyte count, or immunoglobulin level.
Of the 52 patients initially treated with dexamethasone alone, 27 received dexamethasone plus rituximab salvage therapy due to non-responsiveness and of these, 15 (56%) achieved SR. This proportion of responders is similar to that of the dexamethasone + rituximab arm (63%). This suggests that a short course of dexamethasone therapy does not negate the effects of subsequent rituximab treatment; on the contrary, it could be useful for identifying patients who may not require further treatment with rituximab.
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Nevertheless, this variable did not confound the significance of the primary end-point, as evidenced by the finding that low-dose steroids or a single course of IVIg had only transient and no long-term effects on response outcome. 35 No significant differences in the relapse rate, RD and the need for additional ITP therapy were observed in patients who achieved SR following dexamethasone monotherapy or dexamethasone plus rituximab (either front-line or salvage therapy). The risk of relapse after SR was low (~20%), in agreement with the observations of Cheng et al. 6 and the relapse-free survival data of
Mazzucconi et al. 34 Therefore, relapse rate appears to be a potential surrogate of SR, rather than of the treatment regimen.
This study has several limitations. The follow-up analysis is brief in comparison with those following splenectomies 3 , thus limiting the evaluation of the long-term effects of rituximab in disease stabilization and its long-term splenectomy-sparing potential. The early interruption of patient accrual resulted in insufficient power for detecting subtle differences in clinical events between the groups, including safety outcomes. With this in mind, the experimental arm was associated with an increased incidence of any and grade 3-4 adverse events but not of SAEs. Most of the grade 3-4 AEs were drug-related, all AEs were resolved and no deaths were recorded. Longterm follow-up revealed only one delayed toxic event (a case of Herpes zoster), confirming the long-term safety findings for rituximab previously reported in NHL and ITP. In addition to safety, little is known of how rituximab acts in ameliorating the symptoms of ITP.
Better characterization of the immune pathways involved in the pathogenesis of ITP and the corresponding patient pharmacogenetic profiles will aid in the selection of candidates for rituximab therapy. Further studies are warranted in order to confirm the effects of low-dose rituximab 38 and the clinical activity of novel anti-CD20 antibodies that will be available in the near future.
In conclusion, results from this study suggest that the combination of dexamethasone and rituximab improves patient outcomes without compromising the safety profile. This outcome does not appear to be affected by a previous single course of dexamethasone monotherapy. The relatively sustained duration of response observed in some patients suggests a beneficial effect on the underlying disease. This treatment regimen provides an option for second-line therapy, particularly in patients not responding to steroids and as an alternative to splenectomy.
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